Taiko PharmaceuticalTAIKO PHARMACEUTICAL CO., LTD.4574東証プライム医薬品FY ending Dec 2025, consolidated, J-GAAP

What does Taiko Pharmaceutical do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income¥923M

Operating cash flow¥814M

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow¥814M

Free cash flow¥510M

Net income¥923M

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第80期(2025/01/01－2025/12/31)
ID S100XSJ22026-03-24Open
EDINET (FSA Japan)
有価証券報告書－第79期(2024/01/01－2024/12/31)
ID S100VHKD2025-03-28Open
EDINET (FSA Japan)
有価証券報告書－第78期(2023/01/01－2023/12/31)
ID S100T5112024-03-28Open
EDINET (FSA Japan)
有価証券報告書－第77期(2022/01/01－2022/12/31)
ID S100QI1S2023-03-30Open
EDINET (FSA Japan)
有価証券報告書－第76期(令和3年1月1日－令和3年12月31日)
ID S100NS202022-03-30Open
EDINET (FSA Japan)
有価証券報告書－第75期(令和2年4月1日－令和2年12月31日)
ID S100L2I22021-03-30Open

Extracted from XBRL: 46 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.